Basel, Switzerland – May 2, 2024, Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for organ fibrosis and Claudin-1 positive tumors, sponsors the 3rd International Summit on Lung Cancer held May 5-6 in Rome, Italy.

About the International Summit on Lung Cancer
In Italy, lung cancer represents the first cause of death from cancer in men and the third cause in women. Lung cancer treatment is based on the multidisciplinary integration of surgical, medical, and oncological specialties.
During the summit, leading experts in the field of lung cancer discuss clinical questions, with a view to a complete multidisciplinarity, with particular attention to current and future therapeutic options.
The summit is organized by the International Association for the Study of Lung Cancer (IASLC). 

For more information visit the conference website.